Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026

Forte Biosciences, Inc.

2026-Q1 EPS reported -$1.24

Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.
Cash and equivalents $77.0M at Dec 31, 2025, up from $22.2M at Dec 31, 2024.
Phase 2 celiac disease topline data expected in 2026; Phase 1b vitiligo (1H 2026) and alopecia areata data expected in 2026.
Weighted average shares & pre-funded warrants 14.7M vs 2.9M in 2024; CEO highlights FB102 potential in multi-billion markets.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Forte Biosciences, Inc. reported the year ended December 31, 2025 results: net income $(69,375) thousand, EPS $(4.71).

Period: the year ended December 31, 2025
Net income: $(69,375) thousand
EPS: $(4.71)
Result: reported results

Exact text from the filing

Interest income 2,715 1,314 Other expense, net (396 ) (190 ) Total other income, net 2,319 1,124 Net loss before taxes (68,338 ) (35,478 ) Income tax expense 1,037 — Net loss $ (69,375 ) $ (35,478 ) Per share information: Net loss per share - basic and diluted $ (4.71 ) $ (12.17 ) Weighted average share, and pre-funded warrants outstanding, basic and diluted

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-135767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.